Tom 5, Nr 2 (2024)
Artykuł przeglądowy
Opublikowany online: 2024-09-04
Wyświetlenia strony
162
Wyświetlenia/pobrania artykułu
9
Infekcje grzybicze płuc
DOI: 10.5603/pp.98887
Pneum Pol 2024;5(2):77-98.
Streszczenie
Grzybicze zapalenia płuc powinny być elementem diagnostyki różnicowej, w związku z narastającym problemem immunosupresji wśród naszych pacjentów. Wobec niewielkiego rozpowszechnienia, zróżnicowanej symptomatologii oraz metod diagnostycznych, wielokrotnie stanowią niemały problem diagnostyczny wśród lekarzy praktyków. Opóźnienie diagnozy może być poważne w skutkach, tym bardziej iż infekcje te dotyczą zwykle osób z obniżoną odpornością. W poniższym opracowaniu przedstawiono najczęstsze grzybice płucne z charakterystyką patogenów, leczeniem oraz dedykowaną diagnostyką. Celem podsumowania wyżej wymienione dane podsumowano w tabelach umieszczonych na końcu artykułu.
Słowa kluczowe: grzybice płucaspergilozaaspergilomapneumocystozaleczenie grzybic płucdiagnostyka grzybic płucinfekcje oportunistyczne płuc
Referencje
- Thomas C, Limper A. Pneumocystis Pneumonia. New England Journal of Medicine. 2004; 350(24): 2487–2498.
- José RJ, Periselneris JN, Brown JS, et al. Opportunistic and fungal infections of the lung. Medicine (Abingdon). 2012; 40(6): 335–339.
- Alanio A, Hauser PM, Lagrou K, et al. 5th European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71(9): 2386–2396.
- Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71(1): 5–13.
- Sepkowitz K. Pneumocystis carinii Pneumonia Among Patients Without AIDS at a Cancer Hospital. JAMA: The Journal of the American Medical Association. 1992; 267(6): 832.
- Morris A, Netravali M, Kling HM, et al. Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis. 2008; 47(7): e64–e68.
- Kling HM, Shipley TW, Patil SP, et al. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection. Infect Immun. 2010; 78(10): 4320–4330.
- Lundgren B, Lipschik GY, Kovacs JA. Purification and characterization of a major human Pneumocystis carinii surface antigen. J Clin Invest. 1991; 87(1): 163–170.
- Maschmeyer G, Helweg-Larsen J, Pagano L, et al. 6th European Conference on Infections in Leukemia (ECIL-6), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016; 71(9): 2405–2413.
- Lortholary O, Renaudat C, Sitbon K, et al. French Mycosis Study Group. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014; 40(9): 1303–1312.
- Kwon-Chung KJ, Fraser JA, Doering TL, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014; 4(7): a019760.
- Charlier C, Nielsen K, Daou S, et al. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun. 2009; 77(1): 120–127.
- Kim KS. Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Microbiol. 2008; 6(8): 625–634.
- Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995; 21(1): 28–34; discussion 35.
- Sorrell TC, Ellis DH. Ecology of Cryptococcus neoformans. Rev Iberoam Micol. 1997; 14(2): 42–43.
- Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A. 2004; 101(49): 17258–17263.
- Silva EG, Paula CR, de Assis Baroni F, et al. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID). Mycopathologia. 2012; 173(5-6): 445–449.
- Kiertiburanakul S, Wirojtananugoon S, Pracharktam R, et al. Cryptococcosis in human immunodeficiency virus-negative patients. Int J Infect Dis. 2006; 10(1): 72–78.
- Severo C, Xavier M, Gazzoni A, et al. Cryptococcosis in children. Paediatric Respiratory Reviews. 2009; 10(4): 166–171.
- Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011; 52(7): 945–952.
- Warris A, Bjørneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001; 344(14): 1099–1100.
- Hage CA, Carmona EM, Epelbaum O, et al. Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019; 200(5): 535–550.
- Thompson GR, Le T, Chindamporn A, et al. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infect Dis. 2021; 21(12): e364–e374.
- Chen SCA, Perfect J, Colombo AL, et al. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2021; 21(12): e375–e386.
- Li Z, Lu G, Meng G. Pathogenic Fungal Infection in the Lung. Front Immunol. 2019; 10: 1524.
- Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother. 1991; 28 Suppl B: 1–16.
- Saral R. Candida and Aspergillus infections in immunocompromised patients: an overview. Rev Infect Dis. 1991; 13(3): 487–492.
- Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 Suppl 1: e1–e38.
- Asano K, Hebisawa A, Ishiguro T, et al. Japan ABPM Research Program. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 2021; 147(4): 1261–1268.e5.
- Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25(1): 26–34.
- Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012; 54 Suppl 1: S23–S34.
- Hoenigl M, Salmanton-García J, Walsh T, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. The Lancet Infectious Diseases. 2021; 21(8): e246–e257.
- Roden AC, Schuetz AN. Histopathology of fungal diseases of the lung. Semin Diagn Pathol. 2017; 34(6): 530–549.
- Liu Y, Fahle GA, Kovacs JA. Inability to Culture Pneumocystis jirovecii. mBio. 2018; 9(3).
- Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am. 2010; 24(1): 107–138.
- Flori P, Bellete B, Durand F, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol. 2004; 53(Pt 7): 603–607.
- Wilson JW, Limper AH, Grys TE, et al. Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. Diagn Microbiol Infect Dis. 2011; 69(2): 145–152.
- Fujisawa T, Suda T, Matsuda H, et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology. 2009; 14(2): 203–209.
- Oz HS, Hughes WT. Search for Pneumocystis carinii DNA in upper and lower respiratory tract of humans. Diagn Microbiol Infect Dis. 2000; 37(3): 161–164.
- Wood BR, Komarow L, Zolopa AR, et al. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS. 2013; 27(6): 967–972.
- Clancy C, Nguyen MH. Diagnosing Invasive Candidiasis. J Clin Microbiol. ; 2018: 56.
- Mikulska M, Calandra T, Sanguinetti M, et al. Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010; 14(6): R222.
- Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016; 30(1): 179–206.
- Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med. 2008; 29(2): 141–150.
- Nadrous HF, Antonios VS, Terrell CL, et al. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest. 2003; 124(6): 2143–2147.
- Chen SA, Meyer W, Sorrell T. Cryptococcus gattii Infections. Clinical Microbiology Reviews. 2014; 27(4): 980–1024.
- Oshima K, Takazono T, Saijo T, et al. Examination of cryptococcal glucuronoxylomannan antigen in bronchoalveolar lavage fluid for diagnosing pulmonary cryptococcosis in HIV-negative patients. Med Mycol. 2018; 56(1): 88–94.
- Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. Med Mycol. 2019; 57(2): 133–150.
- Baughman RP, Rhodes JC, Dohn MN, et al. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility. Am Rev Respir Dis. 1992; 145(5): 1226–1229.
- Zhang Y, Zhang SX, Trivedi J, et al. Pleural fluid secondary to pulmonary cryptococcal infection: a case report and review of the literature. BMC Infect Dis. 2019; 19(1): 710.
- Kirby T, Rice T. Thoracoscopic lobectomy. The Annals of Thoracic Surgery. 1993; 56(3): 784–786.
- Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011; 53(5): 448–454.
- Fandiño-Devia E, Rodríguez-Echeverri C, Cardona-Arias J, et al. Antigen Detection in the Diagnosis of Histoplasmosis: A Meta-analysis of Diagnostic Performance. Mycopathologia. 2016; 181(3-4): 197–205.
- Richer SM, Smedema ML, Durkin MM, et al. Improved Diagnosis of Acute Pulmonary Histoplasmosis by Combining Antigen and Antibody Detection. Clin Infect Dis. 2016; 62(7): 896–902.
- Hage CA, Davis TE, Fuller D, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest. 2010; 137(3): 623–628.
- Wheat L, Azar M, Bahr N, et al. Histoplasmosis. Infectious Disease Clinics of North America. 2016; 30(1): 207–227.
- Tobón AM, Agudelo CA, Rosero DS, et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals. Am J Trop Med Hyg. 2005; 73(3): 576–582.
- Simon S, Veron V, Boukhari R, et al. Detection of Histoplasma capsulatum DNA in human samples by real-time polymerase chain reaction. Diagn Microbiol Infect Dis. 2010; 66(3): 268–273.
- Tang YW, Li H, Durkin MM, et al. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. Diagn Microbiol Infect Dis. 2006; 54(4): 283–287.
- Martynowicz MA, Prakash UBS. Pulmonary blastomycosis: an appraisal of diagnostic techniques. Chest. 2002; 121(3): 768–773.
- Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev. 2010; 23(2): 367–381.
- Frost HM, Novicki TJ. Blastomyces Antigen Detection for Diagnosis and Management of Blastomycosis. J Clin Microbiol. 2015; 53(11): 3660–3662.
- Klein BS, Vergeront JM, Weeks RJ, et al. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med. 1986; 314(9): 529–534.
- Durkin M, Connolly P, Kuberski T, et al. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin Infect Dis. 2008; 47(8): e69–e73.
- Malo J, Holbrook E, Zangeneh T, et al. Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay. J Clin Microbiol. 2017; 55(3): 893–901.
- Jung J, Kim MY, Lee HJ, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect. 2015; 21(7): 684.e11–684.e18.
- Soubani AO, Qureshi MA. Invasive pulmonary aspergillosis following bone marrow transplantation: risk factors and diagnostic aspect. Haematologia (Budap). 2002; 32(4): 427–437.
- Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996; 100(2): 171–178.
- Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004; 190(3): 641–649.
- Cordonnier C, Botterel F, Ben Amor R, et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect. 2009; 15(1): 81–86.
- Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006; 42(10): 1417–1427.
- Kök M. Characterization of Galactomannan Stabilised Yogurt Drink Using Dynamic Rheology. International Journal of Food Properties. 2010; 13(1): 209–220.
- Busca A, Locatelli F, Barbui A, et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc. 2006; 38(5): 1610–1613.
- Guigue N, Lardeux S, Alanio A, et al. Importance of operational factors in the reproducibility of Aspergillus galactomannan enzyme immune assay. PLoS One. 2015; 10(4): e0124044.
- Cruciani M, Mengoli C, Barnes R, et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2015; 9(9): CD009551.
- Avni T, Levy I, Sprecher H, et al. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol. 2012; 50(11): 3652–3658.
- Donnelly J, Chen S, Kauffman C, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases. 2019; 71(6): 1367–1376.
- Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018; 56(suppl_1): 93–101.
- Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012; 54 Suppl 1: S55–S60.
- Millon L, Scherer E, Rocchi S, et al. Molecular Strategies to Diagnose Mucormycosis. J Fungi (Basel). 2019; 5(1).
- Kelly BT, Pennington KM, Limper AH. Advances in the diagnosis of fungal pneumonias. Expert Rev Respir Med. 2020; 14(7): 703–714.
- Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4): 710–718.
- Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012; 125(1 Suppl): S3–13.
- Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother. 2004; 53(2): 386–389.
- Arendrup MC, Friberg N, Mares M, et al. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect. 2020; 26(11): 1464–1472.
